Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C4H8N2O3.H2O |
| Molecular Weight | 150.1332 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.N[C@@H](CC(N)=O)C(O)=O
InChI
InChIKey=RBMGJIZCEWRQES-DKWTVANSSA-N
InChI=1S/C4H8N2O3.H2O/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H2,6,7)(H,8,9);1H2/t2-;/m0./s1
Asparagine is a non-essential amino acid, which is synthesized in the human body from L-aspartate by Asparagine synthetase. Asparagine is required for the synthesis of many important cellular proteins in normal human cells. Many tumor cells do not have this capacity, due to a lack of the enzyme L-asparagine synthetase, and therefore require an exogenous supply of the amino acid. This amino acid participates in the functions of the brain and nervous system. Asparagine may come from food or be taken as a dietary supplement.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. | 2010-06 |
|
| L-asparaginase and L-asparagine metabolism. | 1970 |
|
| Diminished phenylketonuria in phenylpyruvic oligophrenia after administration of L-glutamine, L-glutamate or L-asparagine. | 1956-06 |
|
| Asparagine in blood plasma. | 1953-06-20 |
Sample Use Guides
500 mg or 1 capsule daily as a dietary supplement or as recommended by a healthcare practitioner.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27126896
HeLa cells were treated with 0.1 mM asparagine and at this concentration, the amino acid promoted cancer cell proliferation in 3 times.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1666924
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID90973512
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
170358
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
1043513
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
C87433
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
100000153357
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
2PD79VF521
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
2PD79VF521
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
5794-13-8
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
SUB26049
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY | |||
|
SUB127325
Created by
admin on Mon Mar 31 17:47:23 GMT 2025 , Edited by admin on Mon Mar 31 17:47:23 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD